Phase 1 trial testing both intranasal and intramuscular administration
WEDNESDAY, July 13, 2022 (HealthDay News) — The National Institutes of Health Clinical Center has begun a phase I trial of a potential universal influenza vaccine, according to an announcement by the agency.
The National Institute of Allergy and Infectious Diseases recently began enrolling 100 adults (aged 18 to 55 years) for the single-site trial. Volunteers will be randomly assigned (1:1:1) to receive two doses of placebo or vaccine spaced 28 days apart. Group A will receive BPL-1357 intramuscularly along with intranasal saline placebo. Group B will receive doses of the candidate vaccine intranasally along with intramuscular placebo. Group C will receive intramuscularly and intranasally delivered placebo at both visits.
BPL-1357 is a whole-virus vaccine consisting of four strains of noninfectious, chemically inactivated, low-pathogenicity avian flu virus. Volunteers will return to the clinic seven times to provide blood and nasal mucosal samples to detect and characterize immune responses.
“Influenza vaccines that can provide long-lasting protection against a wide range of seasonal influenza viruses as well as those with pandemic potential would be invaluable public health tools,” Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, said in a statement.
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children .jpeg)
Most Adults With Moderate-to-Severe Ulcerative Colitis Ineligible for RCTs 
Huge Gap Exists Between Regulatory Authorization, Clinical Validation of AI Medical Devices 
Randomized Trial of Early Vitrectomy Feasible for Postoperative Endophthalmitis .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV 
Barriers to Pediatric Cancer Clinical Trial Participation Identified 
Povorcitinib Beneficial for Moderate-to-Severe Hidradenitis Suppurativa 
